In this new episode of BioTalk, Rip Ballou, MD, VP & Head, GSK Global Vaccines US R&D Center and BHI President & CEO Rich Bendis discuss GSK’s move to the BioHealth Capital Region, their Vaccines Portfolio/Future, and the importance of succeeding in the industry today.
W. Ripley Ballou, MD is Vice President and Head, GSK Global Vaccines U.S. R&D Center in Rockville, MD - Just outside of Washington, DC. Prior to this he was VP and Head, Clinical Research and Translational Science, Vaccine Discovery and Development at GSK Vaccines in Rixensart, Belgium. Previously he served as Deputy Director for Vaccines, Infectious Diseases Development, Global Health at the Bill & Melinda Gates Foundation. Dr. Ballou is an expert in vaccine development and has worked in this field for more than 30 years. Trained in Internal Medicine and Infectious Diseases, he began his work on vaccines at the Walter Reed Army Institute of Research where he led the team that with GlaxoSmithKline co-developed RTS,S, the world’s most advanced malaria vaccine. Dr. Ballou has numerous publications in the field of vaccine development and infectious diseases.